French pharmaceutical giant Sanofi plans to use artificial intelligence to accelerate and optimize its drug development.

Sanofi, one of France’s leading pharmaceutical companies, has announced a collaboration with OpenAI and Formation Bio to advance its drug development. This is reported by the news agency “Reuters”.

Sanofi said in a statement that the collaboration with OpenAI gives the company access to their data. These are used to develop AI models for their biopharmaceutical models. In addition, pharmaceutical company Formation Bio will provide support with additional engineering resources.

According to Reuters, large pharmaceutical companies are increasingly relying on artificial intelligence to find patients for clinical trials more quickly or to reduce the number of people needed for drug testing. This could both speed up drug development and save millions.